Secondary analysis of the PREOPANC-2 trial: venous thromboembolism occurred in 28 of 325 patients (9%) with resectable or borderline resectable pancreatic cancer within 12 months and was associated with shorter overall survival (adjusted HR 2.13).
Secondary analysisn = 325
Willems et al. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial